A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel vs MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT)
British Journal of Dermatology Feb 17, 2018
Morton CA, et al. - The researchers intended to demonstrate the non-inferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared to MAL (a cream containing methyl-aminolevulinate) in the treatment of non-aggressive basal cell carcinoma (BCC) with photodynamic therapy (PDT). BF-200 ALA-PDT was highly efficacious and well-tolerated in the treatment of non-aggressive BCC, with proven non-inferiority to MAL-PDT. This treatment illustrated low recurrence rates in the 1-year. follow-up.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
